🕗 Beyond mRNA: Novavax Gets FDA Approval Ep. 296

MedEvidence! Truth Behind the Data

Send us a text

The FDA has granted full approval to Novavax's COVID-19 vaccine, providing an alternative to mRNA vaccines that works through a different mechanism using proteins and adjuvants. Despite being four years into the pandemic, COVID-19 remains a significant health concern, causing approximately 1 in 200 deaths in the US in 2025.
• Novavax uses bioengineered spike proteins combined with an adjuvant rather than mRNA technology
• FDA approved Novavax for all Americans over 65 and those 12-64 with at least one risk factor
• Risk factors include conditions like asthma, diabetes, and obesity
• Northeast Florida contributed 500 patients to the original Novavax clinical trials
• Encore Research Group is currently enrolling participants for an oral COVID vaccine clinical trial
• Participants in the oral vaccine trial will receive compensation for their time
For more information about participating in the oral COVID vaccine study, visit EncoreDocs.com or call 904-730-0101.
Be a part of advancing science by participating in clinical research.
Have a question for Dr. Koren? Email him at [email protected]
Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube

Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn
Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com
Music: Storyblocks - Corporate Inspired
Thank you for listening!

Chapters

1. Introduction to Dr. Michael Koren (00:00:00)

2. Novavax COVID-19 Vaccine Approval (00:00:52)

3. How Novavax Technology Works (00:01:44)

4. FDA Approval and Risk Factors (00:03:13)

5. New Oral COVID Vaccine Research (00:05:56)

6. Closing and Contact Information (00:07:49)